Characterization of Bovine Adrenal Medulla as a Model of Non-histaminergic Itch

NCT ID: NCT06036589

Last Updated: 2023-09-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-10

Study Completion Date

2022-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

With this experiment, the experimenter wish evaluate the role of TRPA1 on non-histaminergic itch induced by BAM8-22

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

With this experiment, the experimenter wish evaluate the role of TRPA1 on non-histaminergic itch induced by BAM8-22 2 (Bovine Adrenal Medulla), which is found naturally in the human body and which has proved to evoke itch. To evaluate the role of TRPA1 it will be used a TRPA1 agonist

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Itch

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CA application + BAM8-22

Group Type EXPERIMENTAL

CA and BAM8-22

Intervention Type DRUG

CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Vehicle and BAM8-22 application

Intervention Type DRUG

Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

CA application and vehicle

Group Type EXPERIMENTAL

CA

Intervention Type DRUG

CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm

vehicle

Intervention Type DRUG

Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CA and BAM8-22

CA (tran-cinnamaldheyde) solution (in ethanol 5%) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Intervention Type DRUG

Vehicle and BAM8-22 application

Vehicle (ethanol) application and BAM8-22 with inactivate cowhage spicules 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm using inactivate cowhage spicules

Intervention Type DRUG

CA

CA (tran-cinnamaldheyde) solution (in ethanol 5%) application to a previously determined area on the volar forearm

Intervention Type DRUG

vehicle

Vehicle (ethanol) application and inactivate cowhage spicules will be applied to a previously determined area on the volar forearm

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy men and women
* 18-60 years
* Speak and understand English

Exclusion Criteria

* Pregnancy or lactation
* Drug addiction defined as any use of cannabis, opioids or other drugs
* Previous or current history of neurological, dermatological, immunological musculoskeletal, cardiac disorder or mental illnesses that may affect the results (e.g. neuropathy, muscular pain in the upper extremities, etc.)
* Moles, wounds, scars or tattoos in the area to be treated or tested
* Lack of ability to cooperate •
* Current use of medications that may affect the trial such as antihistamines and pain killers.
* Skin diseases
* Consumption of alcohol or painkillers 24 hours before the study days and between these
* Acute or chronic pain
* Participation in other trials within 1 week of study entry (4 weeks in the case of pharmaceutical trials)
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Aalborg University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Giulia Erica Aliotta

Principal Investigator, PhD fellow

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aalborg University

Aalborg, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

N-20190062 3rd project

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Evaluation of MDMA on Startle Response
NCT03181763 COMPLETED PHASE1
Oxytocin and Social Cognition
NCT01606462 COMPLETED PHASE1
Safety of GH001 in Healthy Volunteers
NCT04640831 COMPLETED PHASE1
Causal Mechanisms of Odor-Guided Behavior in Humans
NCT07099092 NOT_YET_RECRUITING EARLY_PHASE1